# Triac Trial II in MCT8 Deficiency Patients

> **NCT02396459** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Rare Thyroid Therapeutics International AB** · enrollment: 22 (actual)

## Conditions studied

- Allan-Herndon-Dudley Syndrome

## Interventions

- **DRUG:** Tiratricol

## Key facts

- **NCT ID:** NCT02396459
- **Lead sponsor:** Rare Thyroid Therapeutics International AB
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-12-07
- **Primary completion:** 2027-07-18
- **Final completion:** 2027-08-18
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2026-02-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02396459

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02396459, "Triac Trial II in MCT8 Deficiency Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02396459. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*